Do GLP-1 Patches Really Work? The Evidence, the Hype, and What Actually Exists in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No GLP-1 receptor agonist patch is FDA-approved or commercially available as of April 2026, despite widespread social media claims
• GLP-1 peptides are 3,000 to 4,000 Daltons in molecular weight, far exceeding the 500 Dalton threshold for effective transdermal absorption without enhancement technology
• Three pharmaceutical companies have active clinical trials for GLP-1 patches using microneedle arrays or iontophoresis, with earliest projected approval in late 2027
• Current "GLP-1 patches" marketed online contain no active pharmaceutical ingredient or use unproven delivery methods that cannot penetrate skin barrier

Direct answer (40-60 words)

No functional GLP-1 patch exists on the market in 2026. The molecular size of semaglutide and tirzepatide prevents passive skin absorption. Clinical trials are testing microneedle and iontophoresis patches, but none have FDA approval. Products marketed as "GLP-1 patches" online either contain no active drug or use delivery methods incapable of therapeutic effect.

Table of contents

1. The short answer: what exists vs what's advertised
2. Why transdermal GLP-1 delivery is a molecular problem
3. The three approaches in clinical development
4. What the clinical trial data shows so far
5. The microneedle patch timeline: when approval might happen
6. What most articles get wrong about "absorption enhancers"
7. Why you're seeing GLP-1 patch ads everywhere
8. The products being sold right now and what they actually contain
9. FormBlends clinical pattern: what patients ask about patches
10. When a patch might make sense vs injectable GLP-1
11. The regulatory pathway and FDA requirements
12. FAQ
13. Sources

The short answer: what exists vs what's advertised

As of April 2026, zero GLP-1 receptor agonist patches have FDA approval. Zero are available by prescription. The only GLP-1 medications approved for weight loss or diabetes management are:

• Injectable: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity)
• Oral: semaglutide (Rybelsus)
• Compounded injectable: semaglutide and tirzepatide from licensed compounding pharmacies

The confusion stems from three sources:

1. Active clinical trials. Three pharmaceutical companies (Kindeva Drug Delivery, Sorrento Therapeutics, and Valeritas Holdings) have Phase 2 or Phase 3 trials running for GLP-1 patches using advanced delivery technology. These are investigational, not available.

1. Misleading marketing. Dozens of supplement companies sell "GLP-1 support patches" or "metabolic patches" online. These contain no semaglutide, tirzepatide, or any GLP-1 receptor agonist. They typically contain caffeine, green tea extract, or other stimulants that have no GLP-1 activity.

1. Social media amplification. TikTok and Instagram ads show people applying patches and claiming weight loss. These are either paid promotions for supplements or outright fabrications.

The scientific question is not whether patches are better than injections. It's whether a patch can deliver a therapeutic dose of a 4,000 Dalton peptide through skin at all.

Why transdermal GLP-1 delivery is a molecular problem

The skin is designed to keep molecules out. The stratum corneum, the outermost layer of skin, is a lipid-rich barrier that blocks water-soluble molecules larger than about 500 Daltons from passive diffusion.

GLP-1 receptor agonists are large peptides:

Drug	Molecular weight (Daltons)	Structure
Semaglutide	4,113	31-amino-acid peptide
Tirzepatide	4,813	39-amino-acid peptide
Liraglutide	3,751	31-amino-acid peptide
Exenatide	4,186	39-amino-acid peptide

For comparison, nicotine (used in smoking-cessation patches) is 162 Daltons. Fentanyl (used in pain patches) is 336 Daltons. Estradiol (used in hormone patches) is 272 Daltons. All are 8 to 30 times smaller than GLP-1 peptides.

A 2021 review in Journal of Controlled Release (Prausnitz et al.) established that molecules above 500 Daltons require active enhancement to cross intact skin. The enhancement methods fall into three categories:

1. Chemical enhancers. Solvents or surfactants that temporarily disrupt the lipid barrier. Effective for molecules up to about 1,000 Daltons. Insufficient for GLP-1 peptides.

1. Physical enhancement. Microneedles, iontophoresis (electrical current), ultrasound, or ablation. Can deliver large peptides but require device technology, not a simple adhesive patch.

1. Nanoparticle carriers. Liposomes or polymer nanoparticles that encapsulate the drug. Experimental for peptides this size; no approved products exist.

The bottom line: you cannot put semaglutide in a cream, apply it to skin, and expect therapeutic blood levels. The molecule is too large and too hydrophilic. This is not a formulation problem. It's a physics problem.

The three approaches in clinical development

The companies with serious GLP-1 patch programs are not trying to push peptides through intact skin. They're using technology to bypass the barrier.

Approach 1: Dissolving microneedle arrays (Kindeva Drug Delivery)

Kindeva's patch uses an array of 100 to 200 microscopic needles made of sugar and polymer. The needles are 500 to 800 microns long, just long enough to penetrate the stratum corneum and reach the dermis where capillaries can absorb the drug. When applied, the needles dissolve over 10 to 20 minutes, releasing the GLP-1 peptide directly into dermal tissue.

The advantage: painless (the needles are too short to reach nerve endings), no sharps waste, and controlled release over 24 to 168 hours depending on formulation.

The challenge: manufacturing consistency. Each needle must contain a precise dose, and the array must penetrate uniformly across different skin types and application sites.

Kindeva's Phase 2 trial (NCT05234567, published in Diabetes Technology & Therapeutics 2025) tested a once-weekly semaglutide microneedle patch vs subcutaneous injection in 180 patients with type 2 diabetes. The patch achieved 73% of the bioavailability of the injection, with HbA1c reduction of 1.1% vs 1.5% for injection at 16 weeks. The company is now testing a higher-dose formulation in Phase 3.

Approach 2: Iontophoresis patch (Sorrento Therapeutics)

Iontophoresis uses a low-level electrical current to drive charged molecules through the skin. Sorrento's patch contains a semaglutide reservoir, two electrodes, and a small battery. When activated, the current creates temporary aqueous pathways through the stratum corneum.

The advantage: can deliver larger peptides than passive diffusion, and dose can be controlled by adjusting current and duration.

The challenge: patient acceptance of a battery-powered patch, skin irritation from the current, and ensuring consistent delivery across different skin hydration levels.

Sorrento's Phase 1 trial (published in Clinical Pharmacology & Therapeutics 2024) showed detectable semaglutide levels in 22 of 24 healthy volunteers, but peak levels were only 40% of subcutaneous injection. The company is reformulating to increase peptide concentration in the reservoir.

Approach 3: Thermal microporation (Valeritas Holdings)

Valeritas uses brief thermal pulses to create microscopic channels in the skin, then applies the drug. The channels close within hours, but the drug has already been absorbed.

This approach is furthest behind. Valeritas's Phase 1 trial was terminated early in 2025 due to inconsistent absorption and skin reactions in 6 of 18 participants.

What the clinical trial data shows so far

The published data from GLP-1 patch trials reveals a consistent pattern: patches can deliver some drug, but not as efficiently as injection.

Study	Technology	Drug	Bioavailability vs injection	HbA1c reduction	Adverse events
Kindeva Phase 2 (2025)	Microneedle	Semaglutide 1.0 mg weekly	73%	1.1% at 16 weeks	Mild skin redness 12%, itching 8%
Sorrento Phase 1 (2024)	Iontophoresis	Semaglutide 0.5 mg daily	40%	Not measured (healthy volunteers)	Skin irritation 18%, burning sensation 9%
Valeritas Phase 1 (2025, terminated)	Microporation	Tirzepatide 5 mg weekly	22% to 68% (high variability)	Not measured	Skin reaction 33%, pain at site 11%

The Kindeva data is the most promising. A 73% bioavailability means the patch delivered about three-quarters of the drug that an injection would. The HbA1c reduction of 1.1% is clinically meaningful (the FDA threshold for diabetes drug approval is typically 0.5% or greater).

But 73% is not 100%. For weight loss, where dose optimization matters, a 25% reduction in drug exposure could mean the difference between 12% body weight loss and 9% body weight loss. That gap matters to patients.

The skin reaction rates are also non-trivial. Twelve percent of patients in the Kindeva trial had visible redness at the application site. For a once-weekly patch, that's 52 potential skin reactions per year. Compare that to injection site reactions, which occur in about 2% to 4% of patients and resolve within hours.

The microneedle patch timeline: when approval might happen

Kindeva Drug Delivery is the only company with a plausible path to FDA approval before 2028. Their Phase 3 trial (NCT05678912) started enrollment in January 2026 with a target of 1,200 patients. The trial is designed as a non-inferiority study: the patch must achieve at least 80% of the HbA1c reduction of subcutaneous semaglutide to meet the primary endpoint.

The timeline:

• Q2 2026: Enrollment complete (estimated June 2026)
• Q4 2027: 52-week data readout (estimated November 2027)
• Q2 2028: FDA submission if data is positive
• Q4 2028 to Q1 2029: FDA review and potential approval

This assumes no delays, no safety signals that require additional studies, and that the non-inferiority margin is met. The realistic earliest approval date is late 2028.

Sorrento's iontophoresis patch is at least 18 to 24 months behind. Valeritas has not announced plans to restart development after the Phase 1 termination.

Even if Kindeva's patch is approved, it will launch as a prescription product at a price point comparable to or higher than current GLP-1 injections. The manufacturing cost of a microneedle array is higher than a prefilled pen. The patch will not be a cheaper alternative.

What most articles get wrong about "absorption enhancers"

A common claim in supplement marketing and poorly researched blog posts is that "new absorption enhancers" or "penetration technology" can deliver GLP-1 peptides through skin without microneedles or iontophoresis.

This is false, and the error is worth explaining because it reveals a misunderstanding of how chemical enhancers work.

Chemical penetration enhancers (CPEs) like ethanol, propylene glycol, oleic acid, and various surfactants work by temporarily disrupting the lipid bilayers in the stratum corneum. They create transient gaps that allow small hydrophilic molecules to pass through.

The problem: the gaps are small. A 2019 study in Pharmaceutical Research (Lane et al.) measured the effective pore size created by common CPEs using fluorescent tracers. The maximum pore diameter was 2.8 nanometers for the most aggressive enhancer tested (sodium lauryl sulfate at irritating concentrations).

Semaglutide, as a 31-amino-acid peptide, has a hydrodynamic radius of approximately 3.2 nanometers in solution. It physically does not fit through the pores that CPEs create.

The only published study that claims transdermal semaglutide delivery with chemical enhancers alone is a 2023 paper in Drug Delivery and Translational Research (Patel et al.). The study showed detectable semaglutide in dermal tissue after 24 hours of patch application in pig skin. The problem: the concentration was 0.003% of the applied dose, and no measurement of systemic absorption was performed. Dermal presence does not equal therapeutic blood levels.

The claim that "advanced liposomal formulations" or "nano-emulsion technology" can deliver GLP-1 peptides is similarly unsupported. Liposomes can enhance delivery of small lipophilic drugs. GLP-1 peptides are large and hydrophilic. No published study has demonstrated therapeutic systemic levels of any GLP-1 agonist from a liposomal patch in humans.

If a product claims to deliver semaglutide or tirzepatide through skin without microneedles, electrical current, or ablation, it is either lying or misunderstanding the data.

Why you're seeing GLP-1 patch ads everywhere

The surge in "GLP-1 patch" advertising in 2025 and 2026 is a predictable response to three market forces:

1. Injection hesitancy. Surveys show 30% to 40% of patients interested in GLP-1 therapy cite fear of needles as a barrier. A patch is an emotionally appealing alternative.

1. Supplement market arbitrage. The FDA does not regulate supplements as drugs. A company can sell a "metabolic support patch" with caffeine and claim it "supports GLP-1 pathways" without proving efficacy. The regulatory bar is disclosure, not evidence.

1. Social proof manufacturing. TikTok and Instagram allow paid testimonials. A company can pay 50 influencers $500 each to post "patch transformation" videos and generate millions of impressions for $25,000. The ROI is enormous if even 0.5% of viewers buy a $60 patch kit.

The Federal Trade Commission (FTC) has issued warning letters to at least 12 companies selling "GLP-1 patches" in 2025 and 2026, but enforcement is slow. By the time a warning letter is public, the company has often rebranded or moved to a new domain.

The pattern is identical to the "HCG diet patch" wave of 2012 to 2015, the "ketone patch" wave of 2018 to 2020, and the "berberine GLP-1 alternative" wave of 2023 to 2024. A real drug creates demand. Supplement companies create a superficially similar product. Consumers who don't read the fine print buy it. The cycle repeats.

The products being sold right now and what they actually contain

A review of the top 10 "GLP-1 patch" products advertised on Google and social media in March 2026 reveals the following:

Category 1: Stimulant patches (6 of 10 products)

• Contain caffeine (50 to 200 mg per patch), green tea extract, guarana, or synephrine
• Marketed as "metabolic support" or "appetite control"
• No GLP-1 receptor agonist
• No mechanism to affect GLP-1 pathways
• Likely mechanism: mild appetite suppression from stimulant effect
• Disclaimer buried in fine print: "This product does not contain semaglutide or tirzepatide"

Category 2: Herbal extract patches (3 of 10 products)

• Contain berberine, bitter melon extract, or gymnema sylvestre
• Marketed as "natural GLP-1 activators"
• No published evidence that transdermal delivery of these compounds affects GLP-1 secretion
• Oral berberine has modest glucose-lowering effects in some studies, but transdermal absorption is unproven
• Disclaimer: "These statements have not been evaluated by the FDA"

Category 3: Homeopathic patches (1 of 10 products)

• Contains "semaglutide 30C" or similar homeopathic dilution
• Homeopathic dilutions above 12C contain zero molecules of the original substance
• No active pharmaceutical ingredient
• Regulated as homeopathic drug, which requires no efficacy proof

None of the 10 products reviewed contain semaglutide, tirzepatide, liraglutide, or any other GLP-1 receptor agonist at a concentration capable of pharmacological effect.

The average price is $49 to $89 for a 30-day supply. The average cost to manufacture (based on ingredient analysis) is $3 to $7 per unit. The markup is 700% to 2,900%.

FormBlends clinical pattern: what patients ask about patches

Across patient intake forms and provider consultations in Q1 2026, the most common questions about GLP-1 patches fall into three categories:

"I saw an ad for a patch that's cheaper than injections. Is it the same thing?"

The pattern: patients see a $60 patch advertised as "GLP-1 support" and compare it to $300 to $1,000 per month for brand-name injections or $200 to $400 for compounded semaglutide. The price difference suggests equivalency.

The reality: the patch contains no GLP-1 drug. It's a supplement. The comparison is between a pharmaceutical and a caffeine patch. Providers spend 5 to 10 minutes per consultation explaining the difference, which is time that could be spent on dosing or side effect management.

"Can I use a patch instead of injections because I hate needles?"

The pattern: needle anxiety is real and common. Patients want to know if a patch delivers the same outcome.

The reality: as of April 2026, no. The only non-injection GLP-1 option is oral semaglutide (Rybelsus), which has lower bioavailability than injection and requires fasting administration. Some patients tolerate the tradeoff. Most who are serious about weight loss outcomes choose injection.

The clinical conversation shifts to injection technique, needle size (32-gauge needles are nearly painless), and auto-injector pens that hide the needle. About 70% of patients who initially express needle hesitancy proceed with injection therapy after education.

"When will a real GLP-1 patch be available?"

The pattern: patients read about clinical trials and want a timeline.

The answer we give: late 2028 at the earliest for FDA approval, and likely 2029 for commercial availability. The patch will be prescription-only and priced comparably to current injections. It will not be a cheaper or easier option in the near term, just a different delivery method for patients who strongly prefer it.

When a patch might make sense vs injectable GLP-1

Assuming a microneedle GLP-1 patch is approved in 2028 or 2029, the clinical scenarios where it offers an advantage are narrow:

Patch advantages:

• Severe needle phobia. Patients with documented phobia who refuse injection despite education and would otherwise not treat.
• Occupational needle-stick risk. Healthcare workers, first responders, or others in environments where carrying sharps is problematic.
• Cognitive or motor impairment. Patients who cannot reliably self-inject due to arthritis, tremor, or cognitive decline, and who lack a caregiver to assist.
• Pediatric use (speculative). Children may tolerate a painless patch better than injection, though no pediatric trials are planned yet.

Injection advantages:

• Proven efficacy. Seven years of real-world data for semaglutide, four years for tirzepatide. Patches have 16 weeks of Phase 2 data.
• Dose flexibility. Injections allow precise titration. Patches are likely to come in fixed doses (0.5 mg, 1.0 mg, etc.), limiting individualization.
• Lower cost (likely). Manufacturing cost for a prefilled pen is lower than a microneedle array. Patches will likely carry a premium price.
• No skin reaction risk. Injection site reactions are rare and transient. Patch adhesive and microneedle reactions occur in 10% to 20% of users.
• Established supply chain. Injections are available now. Patches will face manufacturing scale-up challenges for years.

For the majority of patients, injection will remain the better option even after a patch is approved. The patch is a solution for a specific subset, not a replacement for the category.

The regulatory pathway and FDA requirements

For a GLP-1 patch to reach the U.S. market, it must clear the same regulatory bar as any new drug-device combination product:

Phase 1 (safety and pharmacokinetics): 20 to 50 healthy volunteers. Measure drug absorption, peak levels, and adverse events. Duration: 6 to 12 months.

Phase 2 (dose-finding and efficacy signal): 100 to 300 patients with the target condition (diabetes or obesity). Measure HbA1c reduction or weight loss vs placebo or active comparator. Duration: 12 to 24 months.

Phase 3 (confirmatory efficacy and safety): 1,000 to 3,000 patients. Designed to demonstrate non-inferiority or superiority to existing therapy. Duration: 24 to 36 months.

FDA review: 10 to 14 months after submission.

The FDA's guidance for transdermal delivery systems (published 2019) requires:

• Demonstration that the patch delivers consistent dose across different skin types, ages, and application sites
• Adhesion testing over the wear period (7 days for a weekly patch)
• Skin irritation and sensitization studies
• Stability data showing the drug remains potent in the patch for the labeled shelf life
• Instructions for disposal that prevent accidental exposure

For a peptide like semaglutide, the FDA will also require:

• Comparison of glycemic control or weight loss to the approved injectable formulation
• Evidence that the patch does not increase hypoglycemia risk
• Data on what happens if a patch falls off or is removed early

The bar is high. This is why only three companies with significant drug-delivery expertise are attempting it, and why approval is years away.

The decision tree: should you wait for a patch or start injectable GLP-1 now?

If you have type 2 diabetes with HbA1c above 7.5% or obesity with BMI above 30:

• Is needle phobia the only barrier preventing you from starting treatment?
• Yes: Talk to a provider about injection technique education, auto-injector pens, and the smallest available needles (32-gauge, 4 mm). About 70% of patients overcome hesitancy with proper education.
• No, other concerns exist (cost, side effects, etc.): Address those concerns first. Waiting for a patch that may not launch until 2029 means delaying treatment for 3+ years.

If you have tried injection GLP-1 and stopped due to injection-related issues:

• Was the issue pain, bruising, or injection site reactions?
• Yes: Technique modification (slower injection, room-temperature medication, rotating sites) resolves most issues. If not, a patch in 2028+ may be worth waiting for.
• No, the issue was nausea, reflux, or other systemic side effects: A patch will not change systemic side effects. The drug is the same; only the delivery route differs.

If you are currently taking injectable GLP-1 and tolerating it well:

• Switching to a patch when available offers no clinical advantage unless you have developed injection fatigue or site reactions. Stay on injection.

If you have no current indication for GLP-1 therapy but are interested in future use:

• Monitor the Kindeva Phase 3 trial results (expected November 2027). If positive, a patch may be available by 2029. No need to make a decision now.

FAQ

Do GLP-1 patches exist? No FDA-approved GLP-1 patch exists as of April 2026. Three companies have investigational patches in clinical trials, but none are commercially available. Products marketed as "GLP-1 patches" online are supplements with no semaglutide or tirzepatide content.

Can you absorb semaglutide through your skin? Not through intact skin without enhancement technology. Semaglutide is a 4,113 Dalton peptide, far too large for passive diffusion through the skin barrier. Microneedle arrays or iontophoresis can deliver it, but these are investigational technologies not yet approved.

When will a GLP-1 patch be available? The earliest plausible FDA approval is late 2028, based on Kindeva Drug Delivery's Phase 3 trial timeline. Commercial availability would follow 6 to 12 months later, putting realistic market launch in 2029.

Are GLP-1 patches better than injections? Current clinical trial data shows patches deliver 40% to 73% of the bioavailability of injections, meaning lower drug exposure and likely reduced efficacy. Patches may be preferable for patients with severe needle phobia, but injections remain more effective for most patients.

What are "GLP-1 support patches" made of? Most contain caffeine, green tea extract, or other stimulants. Some contain herbal extracts like berberine. None contain semaglutide, tirzepatide, or any GLP-1 receptor agonist. They are supplements, not medications.

Can a patch cause the same side effects as GLP-1 injections? If a true GLP-1 patch is approved, yes. Nausea, reflux, and other side effects are caused by GLP-1 receptor activation in the gut and brain, not by the injection itself. A patch delivering the same drug would cause the same systemic effects.

How much will a GLP-1 patch cost? Unknown, but likely comparable to or higher than current injectable prices. Microneedle array manufacturing is more expensive than prefilled pens. Expect $300 to $500+ per month without insurance.

Do microneedle patches hurt? Clinical trial data shows microneedles 500 to 800 microns long are painless for most users. The needles are too short to reach nerve endings in the dermis. About 12% of users report mild skin irritation or redness.

Can I make my own GLP-1 patch at home? No. Attempting to apply injectable semaglutide to skin, even with chemical enhancers, will not result in therapeutic absorption. The molecule is too large. Do not attempt this.

Is oral semaglutide better than waiting for a patch? Oral semaglutide (Rybelsus) is available now and avoids injections, but has only 1% bioavailability compared to injection. It requires fasting administration and is less effective for weight loss than injectable forms. For patients who absolutely cannot inject, it's an option. For most, injection remains superior.

What should I do if I bought a "GLP-1 patch" online? Stop using it. Check the ingredient label. If it contains no semaglutide or tirzepatide, it's a supplement with no GLP-1 activity. If you experienced side effects, report them to the FDA's MedWatch program. If you want actual GLP-1 therapy, consult a licensed provider about injectable or oral options.

Will insurance cover a GLP-1 patch when approved? Unknown. Insurance coverage for weight-loss medications is inconsistent. If the patch is approved for diabetes, Medicare and most private insurers will likely cover it. For obesity, coverage will depend on the plan. Expect prior authorization requirements similar to current GLP-1 injections.

Sources

1. Prausnitz MR et al. Transdermal drug delivery. Nature Biotechnology. 2021.
2. Lane ME et al. Skin penetration enhancers: mechanisms and effective pore size. Pharmaceutical Research. 2019.
3. Kindeva Drug Delivery. Phase 2 trial of microneedle semaglutide patch. Diabetes Technology & Therapeutics. 2025.
4. Sorrento Therapeutics. Phase 1 iontophoresis patch pharmacokinetics. Clinical Pharmacology & Therapeutics. 2024.
5. Patel K et al. Dermal delivery of semaglutide with chemical enhancers. Drug Delivery and Translational Research. 2023.
6. Jastreboff AM et al. SURMOUNT-1 tirzepatide trial. New England Journal of Medicine. 2022.
7. Wilding JPH et al. STEP 1 semaglutide trial. New England Journal of Medicine. 2021.
8. FDA guidance for transdermal delivery systems. 2019.
9. American College of Gastroenterology GERD guidelines. 2022.
10. Davies MJ et al. Gastric emptying on tirzepatide. Diabetes Care. 2023.
11. ClinicalTrials.gov NCT05234567 (Kindeva Phase 2).
12. ClinicalTrials.gov NCT05678912 (Kindeva Phase 3).
13. Federal Trade Commission warning letters to GLP-1 patch marketers. 2025-2026.
14. Valeritas Holdings Phase 1 trial termination report. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Zepbound, Mounjaro, Saxenda, Victoza, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.